

O I P E
APR 07 2003Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
3220-69768SERIAL No.
10/050,289APPLICANT
Nichols, et al.FILING DATE
January 16, 2002GROUP
Unknown

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

APR 10 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
	AL						
	AM						
	AN						
	AO						
	AP						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	"Dinapsoline: Characterization of a D1 Dopamine Receptor Agonist in a Rat Model of Parkinson's Disease," Gulwadi, et al. <i>J. Pharm. and Exper. Ther.</i> 296: 338-344 (2001).
AS	"Dyskinesias and Tolerance Induced by Chronic Treatment with a D1 Agonist Administered in Pulsatile or Continuous Mode Do Not Correlate with Changes of Putaminal D1 Receptors in Drug-Naive MPTP Monkeys," Goulet, et al. <i>Brain Res.</i> 719: 129-137 (1996).
AT	"Potential Therapeutic Use of the Selective Dopamine D1 Receptor Agonist, A-86929: An Acute Study in Parkinsonian Levodopa-Primed Monkeys," Grondin et al. <i>Neurology</i> 49: 421-426 (1997).
AU	"Time Interval Between Repeated Injections Conditions the Duration of Motor Improvement to Apomorphine in Parkinson's Disease," Grandas et al. <i>Neurology</i> 42: 1287-1290 (1992).
AV	"Increased or Decreased Locomotor Response in Rats Following Repeated Administration of Apomorphine Depends on Dosage Interval," Castro et al. <i>Psychopharm.</i> 85: 333-339 (1985).
AW	"Time Course of Tolerance to Apomorphine in Parkinsonism," Gancher et al. <i>Clin. Pharmacol. Ther.</i> 52: 504-510 (1992).
AX	"Characterization of the D1 Agonist Dinapsoline in the Unilateral 6-OHDA Lesioned Rat," Taber et al. <i>Society for Neuroscience Abstr.</i> 26: Abstr. 809.3 (2000).
AY	"The Selective Dopamine D1 Receptor Agonist A-86929 Maintains Efficacy with Repeated Treatment in Rodent and Primate Models of Parkinson's Disease," Asin et al. <i>J. Pharm. and Exper. Ther.</i> 281: 454-459 (1997).
AZ	

Examiner


Date Considered

7/14/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BASED ON FORM PTO 1449

INDS02 RVB 575544v1



Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 3220-69768		SERIAL No. 10/050,289.	
		APPLICANT Nichols, et al.			
		FILING DATE January 16, 2002		GROUP Unknown	
		U.S. PATENT DOCUMENTS			
*Examiner Initial	Document Number	Date	Name	Class	Subclass
AA					
AB					
AC					
AD					
AE					
AF					
AG					
AH					
AI					
AJ					
AK					
FOREIGN PATENT DOCUMENTS					
	Document Number	Date	Country	Class	Subclass
AL					
AM					
AN					
AO					
AP					
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
AR	"Persistent Activation of the Dopamine D1 Receptor Contributes to Prolonged Receptor Desensitization: Studies with A-77636," Lin et al. <i>J. Pharm. and Exper. Ther.</i> 276: 1022-1029 (1996).				
AS					
AT					
AU					
AV					
AW					
AX					
AY					
AZ					
Examiner	<i>[Signature]</i>				Date Considered 2/14/03
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

BASED ON FORM PTO 1449